|
Valoración de DCF Petros Pharmaceuticals, Inc. (PTPI)
US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Petros Pharmaceuticals, Inc. (PTPI) Bundle
¡Explore las perspectivas financieras de Petros Pharmaceuticals, Inc. (PTPI) con nuestra calculadora DCF fácil de usar! Ingrese sus suposiciones con respecto al crecimiento, los márgenes y los costos para determinar el valor intrínseco de Petros Pharmaceuticals, Inc. (PTPI) e informar sus decisiones de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.6 | 9.6 | 7.8 | 6.0 | 5.8 | 4.6 | 3.7 | 2.9 | 2.3 | 1.8 |
| Revenue Growth, % | 0 | -38.63 | -18.29 | -23.29 | -2.83 | -20.76 | -20.76 | -20.76 | -20.76 | -20.76 |
| EBITDA | -14.0 | -12.2 | -1.6 | -13.7 | -4.2 | -3.5 | -2.8 | -2.2 | -1.8 | -1.4 |
| EBITDA, % | -89.84 | -127.72 | -20.94 | -229.06 | -72.34 | -76.63 | -76.63 | -76.63 | -76.63 | -76.63 |
| Depreciation | 5.3 | 6.8 | 7.0 | 5.7 | 3.4 | 3.2 | 2.5 | 2.0 | 1.6 | 1.3 |
| Depreciation, % | 34.13 | 70.64 | 89.38 | 95.39 | 58.66 | 69.64 | 69.64 | 69.64 | 69.64 | 69.64 |
| EBIT | -19.3 | -19.0 | -8.6 | -19.4 | -7.6 | -4.6 | -3.7 | -2.9 | -2.3 | -1.8 |
| EBIT, % | -123.98 | -198.36 | -110.33 | -324.46 | -131 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 2.1 | 17.1 | 23.8 | 9.4 | 13.3 | 3.8 | 3.0 | 2.4 | 1.9 | 1.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.6 | 5.2 | 2.5 | 2.1 | 2.2 | 1.6 | 1.3 | 1.0 | .8 | .6 |
| Account Receivables, % | 16.72 | 53.9 | 31.43 | 35.22 | 38.23 | 35.1 | 35.1 | 35.1 | 35.1 | 35.1 |
| Inventories | 2.2 | .8 | .5 | 1.8 | 1.6 | .8 | .6 | .5 | .4 | .3 |
| Inventories, % | 14.15 | 7.96 | 6.65 | 30.29 | 27.66 | 17.34 | 17.34 | 17.34 | 17.34 | 17.34 |
| Accounts Payable | 3.8 | 5.6 | 4.6 | 1.8 | 1.7 | 1.9 | 1.5 | 1.2 | .9 | .7 |
| Accounts Payable, % | 24.24 | 58.68 | 58.35 | 30.15 | 29.43 | 40.17 | 40.17 | 40.17 | 40.17 | 40.17 |
| Capital Expenditure | -.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -0.45926 | -0.04846504 | 0 | 0 | -0.000017175083 | -0.10155 | -0.10155 | -0.10155 | -0.10155 | -0.10155 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -18.9 | -17.7 | -9.0 | -26.2 | -7.6 | -4.5 | -3.6 | -2.8 | -2.3 | -1.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -14.7 | -10.3 | -.1 | -24.2 | -4.2 | .2 | -.9 | -.7 | -.6 | -.5 |
| WACC, % | 6.52 | 6.23 | 6.64 | 6.64 | 6.64 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -10 | |||||||||
| Present Terminal Value | -8 | |||||||||
| Enterprise Value | -10 | |||||||||
| Net Debt | -5 | |||||||||
| Equity Value | -5 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | -2.10 |
What You Will Get
- Real PTPI Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Petros Pharmaceuticals' future performance.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive Data: Petros Pharmaceuticals’ historical financial statements and pre-filled projections.
- Customizable Variables: Modify WACC, tax rates, revenue growth, and EBITDA margins to suit your analysis.
- Real-Time Insights: Observe Petros Pharmaceuticals’ intrinsic value update instantly.
- Intuitive Visualizations: Dashboard graphs showcase valuation outcomes and essential metrics.
- Designed for Precision: A specialized tool for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the prebuilt Excel template with Petros Pharmaceuticals' data included.
- Step 2: Explore the pre-filled sheets and familiarize yourself with the key metrics.
- Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view recalculated results, including Petros Pharmaceuticals' intrinsic value.
- Step 5: Make informed investment decisions or generate reports using the outputs.
Why Choose This Calculator?
- Accurate Data: Real Petros Pharmaceuticals financials ensure reliable valuation results.
- Customizable: Adjust key parameters like growth rates, WACC, and tax rates to match your projections.
- Time-Saving: Pre-built calculations eliminate the need to start from scratch.
- Professional-Grade Tool: Designed for investors, analysts, and consultants.
- User-Friendly: Intuitive layout and step-by-step instructions make it easy for all users.
Who Should Use Petros Pharmaceuticals, Inc. (PTPI)?
- Investors: Gain insights into pharmaceutical investments with a comprehensive analysis tool.
- Healthcare Analysts: Streamline your research with an easy-to-use financial model tailored for the biotech sector.
- Consultants: Effortlessly modify the template for client reports or presentations in the healthcare industry.
- Pharmaceutical Enthusiasts: Enhance your knowledge of drug development and market trends using real-case studies.
- Educators and Students: Utilize it as an effective resource for learning about finance and pharmaceuticals in academic settings.
What the Template Contains
- Pre-Filled Data: Includes Petros Pharmaceuticals’ historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Petros Pharmaceuticals’ profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.